肝移植术后脓毒症:1例报告并国际严重脓毒症和脓毒症休克指南解读

易慧敏; 魏绪霞; 黎利娟; 安玉玲; 吕海金; 易小猛; 刘剑戎; 熊亮; 周密; 陆平兰; 郭煜

doi:10.3969/j.issn.1674-7445.2015.06.006

肝移植术后脓毒症:1例报告并国际严重脓毒症和脓毒症休克指南解读

doi: 10.3969/j.issn.1674-7445.2015.06.006

510630 广州，中山大学附属第三医院外科重症监护室（易慧敏、魏绪霞、黎利娟、安玉玲、吕海金、易小猛、刘剑戎、熊亮、周密、陆平兰）；广东药学院附属第一医院输血科（郭煜）

基金项目:

广州市科技计划项目 2011Y1-0033-1

详细信息

通讯作者:
郭煜, Email:13556032882@126.com

中图分类号: R617;R657.3
计量
- 文章访问数: 158
- HTML全文浏览量: 86
- PDF下载量: 27
- 被引次数: 0
出版历程
- 收稿日期: 2015-09-12
- 网络出版日期: 2021-01-19
- 刊出日期: 2015-11-15

Sepsis after liver transplantation: a report of one case and interpretation of International Guidelines for Management of Severe Sepsis and Septic Shock

Surgical Intensive Care Unit, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information

Corresponding author: Guo Yu, Email: 13556032882@126.com

摘要

摘要: 目的总结肝移植术后脓毒症的治疗经验。方法回顾性分析2014年9月中山大学附属第三医院外科重症监护室收治的1例肝移植术后脓毒症的临床特征及治疗方法, 并复习国际严重脓毒症和脓毒症休克治疗指南(SSC指南)解读及相关文献。结果 1例50岁男性患者在肝移植术后1 d出现高热、血压下降, 诊断为感染性休克, 经过适当的目标导向性液体复苏、抗感染、血液净化等治疗获得缓解, 患者病情稳定出院。结论肝移植术后患者易发生感染, 由感染引起的脓毒症病死率高, 因此一旦发生脓毒症, 临床医师要积极地按照SSC指南进行早期的目标导向性治疗及集束化治疗, 根据病原培养结果选用合适的药物, 降低病死率。
- 肝移植 /
- 感染 /
- 脓毒症 /
- 抗感染 /
- 血液净化
Abstract: Objective To summarize the treatment experience of sepsis after liver transplantation. Methods The clinical features and treatment methods of 1 patient developing sepsis after liver transplantation, who was admitted and treated in the Surgical Intensive Care Unit of the Third Affiliated Hospital of Sun Yat-sen University in September 2014, were retrospectively studied. The interpretation of International Guidelines for Management of Severe Sepsis and Septic Shock (SSC Guidelines) and relevant literature were reviewed. Results One male patient at the age of 50 years old developed high fever and decrease of blood pressure at 1 d after liver transplantation, and was diagnosed as septic shock. The symptoms were relieved after the appropriate treatment like goal-directed fluid resuscitation, anti-infection and blood purification, etc. And the patient was discharged in stable conditions. Conclusions It is easy to develop infection after liver transplantation and the fatality rate of sepsis caused by infection is high. Once the sepsis occurs, clinicians must perform early goal-directed therapy and bundle therapy according to the SSC Guidelines positively, and select the appropriate drugs according to the pathogen culture results in order to reduce the fatality rate.
- Liver transplantation /
- Infection /
- Sepsis /
- Anti-infection /
- Blood purification

HTML全文

参考文献(22)

[1]	Drewry AM, Hotchkiss RS. Sepsis: revising definitions of sepsis[J]. Nat Rev Nephrol, 2015, 11(6):326-328. doi: 10.1038/nrneph.2015.66
[2]	Brown T, Ghelani-Allen A, Yeung D, et al. Comparative effectiveness of physician diagnosis and guideline definitions in identifying sepsis patients in the emergency department[J]. J Crit Care, 2015, 30(1):71-77. doi: 10.1016/j.jcrc.2014.08.009
[3]	Balk RA. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today?[J]. Virulence, 2014, 5(1):20-26. doi: 10.4161/viru.27135
[4]	Gu WJ, Wang F, Bakker J, et al. The effect of goal-directed therapy on mortality in patients with sepsis-earlier is better: a meta-analysis of randomized controlled trials[J]. Crit Care, 2014, 18(5):570. doi: 10.1186/s13054-014-0570-5
[5]	Wan YD, Sun TW, Kan QC, et al. Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies[J]. Crit Care, 2014, 18(2):R71. doi: 10.1186/cc13828
[6]	Page DB, Donnelly JP, Wang HE. Community-, healthcare-, and hospital-acquired severe sepsis hospitalizations in the University Health System Consortium[J]. Crit Care Med, 2015, 43(9):1945-1951. doi: 10.1097/CCM.0000000000001164
[7]	Goodwin AJ, Simpson KN, Ford DW. Volume-mortality relationships during hospitalization with severe sepsis exist only at low case volumes[J]. Ann Am Thorac Soc, 2015, 12(8):1177-1184. http://cn.bing.com/academic/profile?id=1645671388&encoded=0&v=paper_preview&mkt=zh-cn
[8]	胡海清, 周庭银, 唐德羽, 等.肝移植术后革兰阴性杆菌感染的种类及耐药性分析[J].实用医学杂志, 2008, 24(16) :2880-2882. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ200816084.htm Hu HQ, Zhou TY, Tang DY, et al. The analysis on kinds and drug resistance of gram negative bacillus infection after liver transplantation[J]. J Pract Med, 2008, 24(16): 2880-2882. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ200816084.htm
[9]	Fishbain J, Peleg AY. Treatment of acinetobacter infections[J]. Clin Infect Dis, 2010, 51(1):79-84. doi: 10.1086/652975
[10]	Munoz-Price LS, Weinstein RA. Acinetobacter infection[J]. N Engl J Med, 2008, 358(12):1271-1281. doi: 10.1056/NEJMra070741
[11]	Khwannimit B, Bhurayanontachai R. The epidemiology of, and risk factors for, mortality from severe sepsis and septic shock in a tertiary-care university hospital setting[J]. Epidemiol Infect, 2009, 137(9):1333-1341. doi: 10.1017/S0950268809002027
[12]	Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis[J]. Crit Care Med, 2010, 38(2):367-374. doi: 10.1097/CCM.0b013e3181cb0cdc
[13]	Jones AE, Shapiro NI, Trzeciak S, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial[J]. JAMA, 2010, 303(8):739-746. doi: 10.1001/jama.2010.158
[14]	Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012[J]. Crit Care Med, 2013, 41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af
[15]	浙江省早期规范化液体复苏治疗协作组.危重病严重脓毒症/脓毒性休克患者早期规范化液体复苏治疗——多中心、前瞻性、随机、对照研究[J].中国危重病急救医学, 2010, 22(6):331-334. http://www.cqvip.com/QK/97432X/201006/34338168.html Early Goal-Directed Therapy Collaborative Group of Zhejiang Province. The effect of early goal-directed therapy on treatment of critical patients with severe sepsis/septic shock: a multi-center, prospective, randomized, controlled study[J]. Chin Crit Care Med, 2010, 22(6):331-334. http://www.cqvip.com/QK/97432X/201006/34338168.html
[16]	Sopirala MM, Mangino JE, Gebreyes WA, et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant acinetobacter baumannii[J]. Antimicrob Agents Chemother, 2010, 54(11):4678-4683. doi: 10.1128/AAC.00497-10
[17]	Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies[J]. Int J Antimicrob Agents, 2009, 34(1):8.e1-8.e9. http://cn.bing.com/academic/profile?id=1999156712&encoded=0&v=paper_preview&mkt=zh-cn
[18]	刘朝晖, 苏磊, 廖银光, 等.脓毒症机械通气患者营养平衡对临床预后的影响[J].实用医学杂志, 2014, 30(14):2237-2239. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201414019.htm Liu CH, Su L, Liao YG, et al. Impact of energy balance on clinical outcome and complications in septic patients with mechanical ventilation[J]. J Pract Med, 2014, 30(14):2237-2239. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201414019.htm
[19]	Garnacho-Montero J, Amaya-Villar R. Multiresistant acinetobacter baumannii infections: epidemiology and management[J]. Curr Opin Infect Dis, 2010, 23(4):332-339. doi: 10.1097/QCO.0b013e32833ae38b
[20]	Phee LM, Betts JW, Bharathan B, et al. Colistin and fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant acinetobacter baumannii infections[J]. Antimicrob Agents Chemother, 2015, 59(8):4544-4550. doi: 10.1128/AAC.00753-15
[21]	Adibhesami H, Douraghi M, Rahbar M, et al. Minocycline activity against clinical isolates of multidrug-resistant acinetobacter baumannii[J]. Clin Microbiol Infect, 2015, 21(11):e79-e80.DOI: 10.1016/j.cmi.2015.07.007 [Epub ahead of print].
[22]	García-Salguero C, Rodríguez-Avial I, Picazo JJ, et al. Can plazomicin alone or in combination be a therapeutical option against carbapenem-resistant acinetobacter baumannii?[J]. Antimicrob Agents Chemother, 2015, 59(10):5959-5966. doi: 10.1128/AAC.00873-15